M. Cieslik

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

This study shows CDK12 loss drives prostate cancer development and identifies CDK13 as a therapeutic target through paralog-based synthetic lethality in CDK12-mutant tumors.

PIKfyve controls dendritic cell function and tumor immunity

This study shows that PIKfyve inhibition enhances dendritic cell function and improves immunotherapy efficacy in tumor models.

Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients

The paper compiles and provides eight scRNA-seq datasets from nine cancer types, 174 patients, and 90,270 cancer cells to study ICB treatment responses.

Mass spectrometric profiling of HLA-B44 peptidomes provides evidence for tapasin-mediated tryptophan editing

The paper compares HLA-B44 peptidomes with and without tapasin to show tapasin influences C-terminal tryptophan residues and peptide binding affinity.

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors

The paper identifies distinct mutational processes in MHC class I and II genes across primary and metastatic tumors, showing positive selection for mutations disrupting immune interfaces and linking them to immune checkpoint inhibitor response.

HLA-Glyco: A large-scale interrogation of the glycosylated immunopeptidome

The paper develops a computational workflow for glyco-immunopeptidomics, identifies glycosylated MHC class II peptides, and provides a resource with over 3,400 HLA class II N-glycopeptides.

Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways

The paper identifies shared molecular features between H3K27M diffuse midline gliomas and PFA ependymomas, linking them to hindbrain developmental pathways.

Multivalent proteins rapidly and reversibly phase-separate upon osmotic cell volume change

The paper shows multivalent proteins rapidly phase-separate during hyperosmotic stress and reversibly dissolve upon osmotic rescue, impacting transcription termination.

PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism

This study identifies EZHIP as a PRC2 inhibitor in PFA ependymomas that mimics the H3 K27M oncohistone by disrupting PRC2 activity and H3K27me3 levels.